Literature DB >> 21524565

Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection.

Michael N Oxman, Anne A Gershon, Gregory A Poland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21524565      PMCID： PMC5381800          DOI： 10.1016/j.vaccine.2011.04.019

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  28 in total

1.  Aging, immunity, and the varicella-zoster virus.

Authors:  Ann Arvin
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

2.  Recommended adult immunization schedule--United States, 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-02-04       Impact factor: 17.586

3.  Prevention of varicella by zoster immune globulin.

Authors:  P A Brunell; A Ross; L H Miller; B Kuo
Journal:  N Engl J Med       Date:  1969-05-29       Impact factor: 91.245

4.  Immune responses to varicella-zoster in the aged.

Authors:  B L Burke; R W Steele; O W Beard; J S Wood; T D Cain; D J Marmer
Journal:  Arch Intern Med       Date:  1982-02

5.  Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.

Authors:  C Raina MacIntyre; Tony Egerton; Malcolm McCaughey; Janie Parrino; Bernadette V Campbell; Shu-Chih Su; Marco F Pagnoni; Jon E Stek; Jin Xu; Paula W Annunziato; Ivan S F Chan; Jeffrey L Silber
Journal:  Hum Vaccin       Date:  2010-11-01

Review 6.  Zoster vaccine: current status and future prospects.

Authors:  Michael N Oxman
Journal:  Clin Infect Dis       Date:  2010-07-15       Impact factor: 9.079

7.  Community and patient values for preventing herpes zoster.

Authors:  Tracy A Lieu; Ismael Ortega-Sanchez; G Thomas Ray; Donna Rusinak; W Katherine Yih; Peter W Choo; Irene Shui; Ken Kleinman; Rafael Harpaz; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged.

Authors:  R Berger; G Florent; M Just
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

9.  Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection.

Authors:  Shu Li; Ivan S F Chan; Holly Matthews; Joseph F Heyse; Christina Y Chan; Barbara J Kuter; Karen M Kaplan; S J Rupert Vessey; Jerald C Sadoff
Journal:  Pediatr Infect Dis J       Date:  2002-04       Impact factor: 2.129

10.  Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Mona Marin; Dalya Güris; Sandra S Chaves; Scott Schmid; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2007-06-22
View more
  2 in total

Review 1.  Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-07       Impact factor: 11.431

2.  Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.

Authors:  Anthony L Cunningham; Thomas C Heineman; Himal Lal; Olivier Godeaux; Roman Chlibek; Shinn-Jang Hwang; Janet E McElhaney; Timo Vesikari; Charles Andrews; Won Suk Choi; Meral Esen; Hideyuki Ikematsu; Martina Kovac Choma; Karlis Pauksens; Stéphanie Ravault; Bruno Salaun; Tino F Schwarz; Jan Smetana; Carline Vanden Abeele; Peter Van den Steen; Ilse Vastiau; Lily Yin Weckx; Myron J Levin
Journal:  J Infect Dis       Date:  2018-05-05       Impact factor: 5.226
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.